Silence Therapeutics reported $57.19M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
AstraZeneca USD 8.14B 1.08B Sep/2025
Autolus Therapeutics Ltd USD 86.12M 37.7M Sep/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Novartis USD 9.56B 2.9B Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Silence Therapeutics USD 57.19M 4.77M Jun/2025